Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16967416 | 1.00 | ADRB2 (0.52) | ADRB2CYP2C9CYP2C19MEN1CYP2D6 | |
| SCHEMBL16967393 | 1.00 | ADRB2 (0.52) | ADRB2CYP2C9CYP2C19MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL20521971 | 0.98 | ADRB2 (0.50) | ADRB2CYP2C9CYP2C19MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL20521974 | 0.98 | ADRB2 (0.50) | ADRB2CYP2C9CYP2C19MEN1CYP2D6 | |
| SCHEMBL25178201 | 0.82 | ESR1 (0.46) | CYP2C9CYP2C19MEN1CYP2D6KMT2A | |
| SCHEMBL5862033 | 0.82 | DPP4 (0.54) | CYP2D6LMNA | |
| SCHEMBL16967371 | 0.82 | DPP4 (0.54) | CYP2D6LMNA | |
| SCHEMBL3886489 | 0.82 | DPP4 (0.54) | CYP2D6LMNA | |
| SCHEMBL804233 | 0.82 | DPP4 (0.54) | CYP2D6LMNA | |
| SCHEMBL4674647 | 0.82 | DPP4 (0.54) | CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301875-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| EP-4204812-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| EP-4151633-A1 | INTERMEDIATES OF ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2023-03-14 | — | — | US | disclosed |
| WO-2022185260-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022043930-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-03 | — | — | WO | disclosed |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| EP-3601272-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | Astex Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| WO-2018178691-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018178679-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| EP-3356350-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7041667-B1 | CCR5 modulators | PFIZER, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1013276-A1 | Aminoazacycloalkanes as CCR5 modulators | PFIZER INC. (US) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | ADRB2 3848/4885CYP2C9 2188/4885CYP2C19 2466/4885 |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | SKP2, MDM2, TP53 | ADRB2 4183/4885CYP2C9 4773/4885CYP2C19 4690/4885 |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | ADRB2 2046/4885CYP2C9 1315/4885CYP2C19 1637/4885 |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | MDM2, TP53, TP53BP1 | ADRB2 3341/4885CYP2C9 1924/4885CYP2C19 1987/4885 |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | IRF2BP2, BST2, IRF3 | ADRB2 2880/4885CYP2C9 4734/4885CYP2C19 4737/4885 |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | ADRB2 420/4885CYP2C9 443/4885CYP2C19 1023/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | ADRB2 3341/4885CYP2C9 1924/4885CYP2C19 1987/4885 |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | ADRB2 3848/4885CYP2C9 2188/4885CYP2C19 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.